Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis
NCT07548853Phase 3Recruiting
- Sponsor
- Taisho Pharmaceutical
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of TS-172 in hyperphosphatemia, sponsored by Taisho Pharmaceutical. Primary endpoint: Achievement rate of the target serum phosphorus level at 8 weeks. Started May 2026; status: recruiting.
02
Drugs
TS-172
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT07548853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07548853.